By Deena Beasley May 5 (Reuters) - Use of Gilead Sciences' Yeztugo, a twice-yearly injection to prevent HIV infection, has ...

Gilead Sciences' twice-yearly HIV prevention injection Yeztugo has gained users since its June launch, but adoption is slowed by insurance coverage gaps, patient preference for pills, and concerns ...

The US Food and Drug Administration (FDA) announced late Monday that it would eliminate the risk evaluation and mitigation strategy (REMS) for Gilead’s Truvada (emtricitabine/tenofovir disoproxil ...

As part of a years-long effort by PrEP4ALL and other HIV groups to get Gilead Sciences, a pharmaceutical company, to lower ...

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported Wednesday. In clinical trials, the drug nearly eliminated HIV’s spread among ...

Long-acting injections given once every two months can prevent HIV at least as well as daily pills for gay and bisexual men and transgender women, according to interim study results released May 18 by ...

WASHINGTON, DC — The Food and Drug Administration announced a first-of-its-kind Monday -- it approved a medication to be used for reducing the risk of contracting the virus that causes AIDS. The drug ...

Women need daily doses of the antiviral medication Truvada to prevent HIV infection while men only need two doses per week due to the way the drug accumulates in different body tissues, according to a ...

Lenacapavir, a twice-yearly injectable antiretroviral, demonstrated 100% effectiveness for preventing HIV acquisition in a large study of young cisgender women in Africa, Gilead Sciences announced ...

A Food and Drug Administration (FDA) panel is debating whether to make history by recommending approval of the first drug to prevent HIV infection. The advisory committee is expected to vote on ...